<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentamidine (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentamidine (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentamidine (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="104538" href="/d/html/104538.html" rel="external">see "Pentamidine (systemic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="104536" href="/d/html/104536.html" rel="external">see "Pentamidine (systemic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F44485848"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pentam</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F44485851"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent;</li>
<li>
                        Antiprotozoal</li></ul></div>
<div class="block doa drugH1Div" id="F44485882"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42a909c7-7064-4de5-bbc9-e79560c03eac">Leishmaniasis, visceral, secondary prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis, visceral, secondary prophylaxis (off-label use): Note: </b>For patients in East Africa coinfected with HIV and at high risk of visceral leishmaniasis relapse (eg, CD4 count &lt;200 cells/mm<sup>3</sup>, not receiving antiretroviral therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 300 mg once every 3 to 4 weeks until CD4 count &gt;350 cells/mm<sup>3</sup> or HIV viral load undetectable ≥6 months and no evidence of visceral leishmaniasis relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26431253','lexi-content-ref-29020217','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26431253','lexi-content-ref-29020217','lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="473eff5c-78ea-4576-a487-f76a5a5e1a73">Pneumocystis pneumonia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis </i>pneumonia, treatment (alternative agent):</b>
<b>IV:</b> 4 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>) for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>); may reduce to 2 to 3 mg/kg/dose once daily if toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31077616','lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31077616','lexi-content-ref-HHS.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d0d55cf-4fa5-497e-bec0-93c744c85f9e">West African trypanosomiasis, first-stage disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>West African trypanosomiasis (<i>Trypanosoma brucei gambiense</i> infection; sleeping sickness), first-stage disease (off-label use):</b>
<b>IM, IV:</b> 4 mg/kg once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991413"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">IV: The FDA-approved labeling recommends that caution should be used in patients with renal impairment; however, no specific dosage adjustment guidelines are available. The following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer 4 mg/kg every 24 to 36 hours.</p></div>
<div class="block doha drugH1Div" id="F50988649"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Use with caution.</p></div>
<div class="block doe drugH1Div" id="F44485883"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F44485881"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="104536" href="/d/html/104536.html" rel="external">see "Pentamidine (systemic): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="64f9f80a-c63b-4d2f-a59a-32d389d8a789">
<i>Pneumocystis jirovecii</i> pneumonia, prophylaxis in oncology patients and solid organ transplant recipients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii</i> pneumonia (PCP), prophylaxis (primary and secondary) in oncology patients (including hematopoietic stem cell transplant recipients) and solid organ transplant recipients (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 4 mg/kg/dose every 3 to 4 weeks; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25712369','lexi-content-ref-17635000','lexi-content-ref-27164533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25712369','lexi-content-ref-17635000','lexi-content-ref-27164533'])">Ref</a></span>); administration as frequently as every 2 weeks has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26418240','lexi-content-ref-28466513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26418240','lexi-content-ref-28466513'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8f01ae1-8bb4-46b0-a53d-24f5962b66de">
<i>Pneumocystis jirovecii</i> pneumonia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis jirovecii </i>pneumonia (PCP), treatment (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Non-HIV-exposed/-infected: Infants, Children, and Adolescents: IM, IV: 4 mg/kg/dose once daily for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV: 4 mg/kg/dose once daily; if clinical improvement after 7 to 10 days of therapy, may change to an oral regimen to complete a 21-day course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 4 mg/kg/dose once daily for 21 days; may reduce to 3 mg/kg/dose once daily if toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4bda54e-643d-436b-aff3-9ab805abf279">African trypanosomiasis, first-stage disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>African trypanosomiasis (sleeping sickness; <i>T. brucei gambiense</i> infection), first-stage disease (without CNS involvement), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV: 4 mg/kg/dose once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-31449367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-31449367'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51152558"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no specific dose adjustments provided in the manufacturer's labeling, has not been studied; use with caution. The following guidelines have been used by some clinicians based on usual pediatric dose of 4 mg/kg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 30 mL/minute/1.73 m<sup>2</sup>: Administer 4 mg/kg/dose every 36 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup> and peritoneal dialysis: Administer 4 mg/kg/dose every 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: Administer 4 mg/kg/dose every 48 hours, after dialysis on dialysis days.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: 4 mg/kg/dose every 48 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy: No dosage adjustment required.</p></div>
<div class="block dohp drugH1Div" id="F51152559"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer's labeling; has not been studied. Use with caution.</p></div>
<div class="block adr drugH1Div" id="F44485866"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Local: Injection site reaction (intramuscular: 11%; includes sterile abscess, necrosis, pain, induration) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renal: Renal insufficiency (29%), increased serum creatinine (24%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Confusion (≤2%), hallucinations (≤2%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (3%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Endocrine &amp; metabolic: Hypoglycemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Anorexia (≤6%), nausea (≤6%), dysgeusia (2%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic &amp; oncologic: Leukopenia (10%), thrombocytopenia (3%), anemia (1%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepatic: Increased liver enzymes (9%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renal: Azotemia (9%), increased blood urea nitrogen (7%) </p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acute pancreatitis, acute rhinitis, ageusia, amnesia, anaphylaxis, anosmia, anxiety, arthralgia, asthma, blepharitis, blurred vision, bronchitis, bronchospasm, cardiac arrhythmia, cerebrovascular accident, chest congestion, chest tightness, chills, confusion, conjunctivitis, contact lens intolerance, cough, cyanosis, depression, dermatitis, desquamation, diabetes mellitus, diabetic ketoacidosis, diarrhea, disseminated intravascular coagulation, dizziness, drowsiness, dry hair, dyspepsia, dyspnea, emotional lability, eosinophilia, eosinophilic pneumonitis, erythema, extravasation (tissue ulceration, necrosis, and/or sloughing), eye pain, flank pain, gag reflex, hair breakage, headache, hearing loss, hematochezia, hematuria, hemoptysis, hepatic insufficiency, hepatitis, hepatomegaly, hyperglycemia, hyperkalemia, hypersensitivity reaction, hypertension, hyperventilation, hypocalcemia, hypoesthesia, hypomagnesemia, insomnia, interstitial pneumonitis, laryngitis, laryngospasm, melena, nasal congestion, nephritis, nervousness, neuralgia, neuropathy, neutropenia, night sweats, palpitations, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, phlebitis, pleurisy, pneumothorax, prolonged prothrombin time, pruritus, pulmonary disease, rales, renal failure, renal insufficiency, rhinitis, seizure, serious infection (extrapulmonary pneumocystosis), sialorrhea, splenomegaly, Stevens-Johnson syndrome, ST segment changes on ECG, syncope, tachycardia, tachypnea, torsades de pointes, tremor, unsteady gait, urinary incontinence, urticaria, vasodilation, vasculitis, ventricular tachycardia, vertigo, vomiting, xeroderma, xerostomia </p></div>
<div class="block coi drugH1Div" id="F44485863"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pentamidine isethionate or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F44485864"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypotension: Severe hypotension (some fatalities) has been observed, even after a single dose. May occur with either IV or IM administration, although more common with rapid IV administration. Monitor blood pressure during (and after) infusion.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• QT prolongation: May cause QT prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Stevens-Johnson syndrome: Has been reported with use.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cardiovascular disease: Use with caution in patients with preexisting cardiovascular disease; hyper-/hypotension and arrhythmia, including ventricular tachycardia (eg, torsade de pointes) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Diabetes: Use with caution in patients with diabetes mellitus; hyper-/hypoglycemia and pancreatic islet cell necrosis with hyperinsulinemia has been reported. Symptoms may occur months after therapy; monitor blood glucose daily on therapy and periodically thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Intravenous pentamidine is an irritant with vesicant-like properties. Ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. Ulceration, tissue necrosis, and/or sloughing have been reported with extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hematologic disorders: Use with caution in patients with current evidence and/or prior history of hematologic disorders; anemia, leukopenia and/or thrombocytopenia have been reported. Concurrent use with other bone marrow suppressants may increase the risk for myelotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypocalcemia: Use with caution in patients with hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Pancreatitis: Use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels; acute pancreatitis (with fatality) has been reported. Discontinue pentamidine if signs/symptoms of acute pancreatitis occur. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QTc interval.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Nephrotoxic drugs: Concurrent use with other nephrotoxic drugs may increase the risk for nephrotoxicity.</p></div>
<div class="block foc drugH1Div" id="F44485901"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as isethionate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pentam: 300 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F44485850"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F44485903"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Pentam Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $200.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Pentamidine Isethionate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $112.50 - $180.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872016"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as isethionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F44485887"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer deep IM.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse slowly over 60 to 120 minutes; rapid IV administration can cause severe hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614616"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer deep IM.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer by slow IV infusion over a period of at least 60 to 120 minutes; rapid IV administration can cause severe hypotension.</p>
<p style="text-indent:-2em;margin-left:6em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F44485855"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis</i> pneumonia, treatment: </b>Treatment of pneumonia caused by <i>Pneumocystis jirovecii.</i></p></div>
<div class="block off-label drugH1Div" id="F44485856"><span class="drugH1">Use: Off-Label: Adult</span><p>Leishmaniasis, visceral, secondary prophylaxis; West African trypanosomiasis (Trypanosoma brucei gambiense infection; sleeping sickness), first stage</p></div>
<div class="block cyt drugH1Div" id="F44486436"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F44486433"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of Pentamidine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Pentamidine (Systemic) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: May enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Pentamidine (Systemic) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: Pentamidine (Systemic) may enhance the adverse/toxic effect of Foscarnet. The specific toxicities may include hypocalcemia, renal failure, and QT-prolongation.  Management: Consider alternatives to this combination when possible.  If this combination must be used, monitor patients more closely for hypocalcemia, renal dysfunction, and QT interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Pentamidine (Systemic) may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to pentamidine or mequitazine when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: Pentamidine (Systemic) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of Pentamidine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Pentamidine (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Pentamidine (Systemic) may enhance the QTc-prolonging effect of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F44485860"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pentamidine crosses the human placenta (Fortunato 1989; Schwebke 1995).</p>
<p style="text-indent:0em;margin-top:2em;">Intravenous pentamidine can be used as an alternative treatment in pregnant females with HIV infection for mild to moderate <i>Pneumocystis </i>pneumonia (PCP) (HHS [OI adult 2020]). Pentamidine may be used to treat stage one trypanosomiasis caused by <i>T. brucei gambiense </i>(CDC 2020); information related to treatment of pregnant females for this indication is limited (Pohlig 2016).</p></div>
<div class="block brc drugH1Div" id="F44485862"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pentamidine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. Females with HIV infection should completely avoid breastfeeding to decrease the potential transmission of HIV (HHS [perinatal 2019]).</p></div>
<div class="block mop drugH1Div" id="F44485892"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs, renal function tests, blood glucose, serum potassium and calcium, CBC and platelets; ECG; BP (during and after infusion).</p></div>
<div class="block pha drugH1Div" id="F44485871"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with microbial RNA/DNA, phospholipids and protein synthesis, through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA</p></div>
<div class="block phk drugH1Div" id="F44485873"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Binds to tissues and plasma protein; high concentrations are found in the liver, kidney, adrenals, spleen, lungs, and pancreas; poor penetration into CNS; IV: 821 ± 535 L; IM: 2724 ± 1066 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: 6.4 ± 1.3 hours; IM: 9.4 ± 2 hours; may be prolonged with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (IV: ≤12% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51198703"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Pentamidine may accumulate in renal failure.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45524660"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Pentamidina combino</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pentacarinat</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pentamidine isethi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pentamidine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007: p 73, 160.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Parasites - African trypanosomiasis (also known as sleeping sickness): Resources for health professionals. <a href="https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/sleepingsickness/health_professionals/index.html</a>. Updated August 12, 2020. Accessed February 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25712369">
<a name="25712369"></a>Clark A, Hemmelgarn T, Danziger-Isakov L, Teusink A. Intravenous pentamidine for Pneumocystis carinii/jiroveci pneumonia prophylaxis in pediatric transplant patients. <i>Pediatr Transplant</i>. 2015;19(3):326-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/25712369/pubmed" id="25712369" target="_blank">25712369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1424505">
<a name="1424505"></a>Comtois R, Pouliot J, Gervais S, et al. High Pentamidine Levels Associated With Hypoglycemia and Azotemia in a Patient With <i>Pneumocystis carinii</i> Pneumonia. <i>Diagn Microbiol Infect Dis</i>. 1992;15(6):523-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/1424505/pubmed" id="1424505" target="_blank">1424505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3190049">
<a name="3190049"></a>Conover B, Goldsmith JC, Buehler BA, et al. Aerosolized Pentamidine and Pregnancy. <i>Ann Intern Med. </i>1988;109(11):927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/3190049/pubmed" id="3190049" target="_blank">3190049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1984463">
<a name="1984463"></a>Conte JE Jr. Pharmacokinetics of Intravenous Pentamidine in Patients With Normal Renal Function or Receiving Hemodialysis. <i>J Infect Dis</i>. 1991;163(1):169-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/1984463/pubmed" id="1984463" target="_blank">1984463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1477438">
<a name="1477438"></a>Cortese LM, Gasser RA, Jr, Bjornson DC, et al. Prolonged Recurrence of Pentamidine-Induced Torsade de Pointes. <i>Ann Pharmacother</i>. 1992;26(11):1365-1369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/1477438/pubmed" id="1477438" target="_blank">1477438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3728484">
<a name="3728484"></a>De NC, Alam AS, Kapoor JN. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. <i>Am J Hosp Pharm</i>. 1986;43(6):1486-1488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/3728484/pubmed" id="3728484" target="_blank">3728484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26431253">
<a name="26431253"></a>Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. <i>PLoS Negl Trop Dis</i>. 2015;9(10):e0004087. doi:10.1371/journal.pntd.0004087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/26431253/pubmed" id="26431253" target="_blank">26431253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020217">
<a name="29020217"></a>Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial. <i>Clin Infect Dis</i>. 2018;66(3):444-451. doi:10.1093/cid/cix807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/29020217/pubmed" id="29020217" target="_blank">29020217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077616">
<a name="31077616"></a>Fishman JA, Gans H; AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13587. doi:10.1111/ctr.13587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/31077616/pubmed" id="31077616" target="_blank">31077616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2929699">
<a name="2929699"></a>Fortunato SJ, Bawdon RE. Determination of Pentamidine Transfer in the <i>in vitro</i> Perfused Human Cotyledon With High-Performance Liquid Chromatography. <i>Am J Obstet Gynecol</i>. 1989;160(3):759-761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/2929699/pubmed" id="2929699" target="_blank">2929699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8331631">
<a name="8331631"></a>Gates HS Jr, Barker CD. <i>Pneumocystis carinii</i> Pneumonia in Pregnancy. A Case Report. <i>J Reprod Med</i>. 1993;38(6):483-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/8331631/pubmed" id="8331631" target="_blank">8331631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goa.1">
<a name="Goa.1"></a>Goa KL, Campoli-Richards DM. Pentamidine Isethionate. A Review of Its Antiprotozoal Activity, Pharmacokinetic Properties and Therapeutic Use in <i>Pneumocystis carinii</i> Pneumonia. <i>Drugs</i>. 1987;33(3):242-258.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7956402">
<a name="7956402"></a>Ito S, Koren G. Estimation of Fetal Risk From Aerosolized Pentamidine in Pregnant Healthcare Workers. <i>Chest</i>. 1994;106(5):1460-1462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/7956402/pubmed" id="7956402" target="_blank">7956402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635000">
<a name="17635000"></a>Kim SY, Dabb AA, Glenn DJ, et al. Intravenous Pentamidine is Effective as Second Line Pneumocystis Pneumonia Prophylaxis in Pediatric Oncology Patients. <i>Pediatr Blood Cancer</i>. 2008;50(4):779-783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/17635000/pubmed" id="17635000" target="_blank">17635000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26418240">
<a name="26418240"></a>Levy ER, Musick L, Zinter MS, et al. Safe and Effective Prophylaxis with bimonthly intravenous pentamidine in the pediatric hematopoietic stem cell transplant population. <i>Pediatr Infect Dis J</i>. 2016;35(2):135-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/26418240/pubmed" id="26418240" target="_blank">26418240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28466513">
<a name="28466513"></a>Montoya Tamayo C, Bossacoma Busquets F, Vinent Genestar J, Fortuny Guasch C, Santa-Maria López V, Rives S. Intravenous pentamidine for Pneumocystis pneumonia prophylaxis in children undergoing autologous hematopoietic stem cell transplant. <i>Pediatr Blood Cancer</i>. 2017;64(11):10.1002/pbc.26558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/28466513/pubmed" id="28466513" target="_blank">28466513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nanda.1">
<a name="Nanda.1"></a>Nanda D, Tannenbaum I, Landesman S, et al. Pentamidine Prophylaxis in Pregnancy. <i>Am J Obstet Gynecol</i>. 1992;166:387.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8530781">
<a name="8530781"></a>Pelucio MT, Rothenhaus T, Smith M, et al. Fatal Pancreatitis as a Complication of Therapy for HIV Infection. <i>J Emerg Med</i>. 1995;13(5):633-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/8530781/pubmed" id="8530781" target="_blank">8530781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pentam.1">
<a name="Pentam.1"></a>Pentam 300 (pentamidine isethionate) injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Pentamidine isethionate injection [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26882015">
<a name="26882015"></a>Pohlig G, Bernhard SC, Blum J, et al. Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial.<i> PLoS Negl Trop Dis</i>. 2016;10(2):e0004363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/26882015/pubmed" id="26882015" target="_blank">26882015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. I. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7548518">
<a name="7548518"></a>Schwebke K, Fletcher CV, Acosta EP, et al. Pentamidine Concentrations in a Mother With AIDS and in Her Neonate. <i>Clin Infect Dis</i>. 1995;20(6):1569-1570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/7548518/pubmed" id="7548518" target="_blank">7548518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1875979">
<a name="1875979"></a>Smaldone GC, Vinciguerra C, Marchese J. Detection of Inhaled Pentamidine in Health Care Workers. <i>N Engl J Med</i>. 1991;325(12):891-892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/1875979/pubmed" id="1875979" target="_blank">1875979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27164533">
<a name="27164533"></a>Solodokin LJ, Klejmont LM, Scipione MR, Dubrovskaya Y, Lighter-Fisher J, Papadopoulos J. Safety and effectiveness of intravenous pentamidine for prophylaxis of Pneumocystis jirovecii pneumonia in pediatric hematology/oncology patients. <i>J Pediatr Hematol Oncol</i>. 2016;38(6):e180-e185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/27164533/pubmed" id="27164533" target="_blank">27164533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1542322">
<a name="1542322"></a>Sperling RS, Stratton P, O'Sullivan MJ, et al. A Survey of Zidovudine Use in Pregnant Women With Human Immunodeficiency Virus Infection. <i>N Engl J Med</i>. 1992;326(13):857-861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/1542322/pubmed" id="1542322" target="_blank">1542322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. Available at <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated December 24, 2019. Accessed January 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31449367">
<a name="31449367"></a>
<i>WHO interim guidelines for the treatment of gambiense human African trypanosomiasis</i>. Geneva: World Health Organization; August 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-systemic-drug-information/abstract-text/31449367/pubmed" id="31449367" target="_blank">31449367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. https://www.who.int/publications/i/item/9789240048294. Updated June 7, 2022. Accessed October 13, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 104533 Version 136.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
